Akero Therapeutics Inc buy UBS Group AG
Start price
05.03.24
/
50%
€26.60
Target price
05.03.25
€38.62
Performance (%)
-31.37%
Price
03.05.24
€18.26
Summary
This prediction is currently active. The BUY prediction by UBS_Group_AG for Akero Therapeutics Inc is performing very badly with a performance of -31.37%. This prediction currently runs until 05.03.25. The prediction end date can be changed by UBS_Group_AG at any time. UBS_Group_AG has 50% into this predictionPerformance without dividends (%)
Name | 1w | 1m |
---|---|---|
Akero Therapeutics Inc | -6.457% | -6.457% |
iShares Core DAX® | -0.922% | -1.993% |
iShares Nasdaq 100 | 0.371% | -0.868% |
iShares Nikkei 225® | 2.224% | -5.187% |
iShares S&P 500 | -0.026% | -0.918% |
Comments by UBS_Group_AG for this prediction
In the thread Akero Therapeutics Inc diskutieren
Akero Therapeutics, Inc. (NASDAQ: AKRO) had its price target raised by analysts at UBS Group AG from $39.00 to $42.00. They now have a "buy" rating on the stock.
Ratings data for AKRO provided by MarketBeat
Stopped prediction by UBS_Group_AG for Akero Therapeutics Inc
Akero Therapeutics Inc
Start price
Target price
Perf. (%)
€14.00
12.10.23
12.10.23
€37.01
12.10.24
12.10.24
30.39%
03.05.24
03.05.24
Akero Therapeutics Inc
Start price
Target price
Perf. (%)
€46.20
28.08.23
28.08.23
€76.75
28.08.24
28.08.24
-60.49%
03.05.24
03.05.24